Association of ApoE and LRP mRNA levels with dementia and AD neuropathology

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 628.e1-628.e14

  Akram, Afia ^a   Schmeidler, James ^a   Katsel, Pavel ^a   Hof, Patrick R ^a   Haroutunian, Vahram ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; APOE; Dementia; Hippocampus; LRP

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA;

AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; AUTOPSY; BRAAK NEUROPATHOLOGICAL STAGING; CHOLESTEROL HOMEOSTASIS; CLINICAL FEATURE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HIPPOCAMPUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INFERIOR TEMPORAL GYRUS; LRP GENE; MALE; NEUROPATHOLOGY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE POLYMERASE CHAIN REACTION; RATING SCALE; SENILE PLAQUE; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING;

EID: 84855767006     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.04.010     Document Type: Article

References (117)

1. Akram A., Schmeidler J., Katsel P., Hof P.R., Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Res 2010, 1318:167-177.
2. Arélin K., Kinoshita A., Whelan C.M., Irizarry M.C., Rebeck G.W., Strickland D.K., Hyman B.T. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res 2002, 104:38-46.
3. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo P., Ghetti B., Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet 1997, 17:263-264.
4. Barton A.J., Pearson R.C., Najlerahim A., Harrison P.J. Pre- and postmortem influences on brain RNA. J. Neurochem 1993, 61:1-11.
5. Bauer D.E., Haroutunian V., McCullumsmith R.E., Meador-Woodruff J.H. Expression of four housekeeping proteins in elderly patients with schizophrenia. J. Neural Transm 2009, 116:487-491.
6. Beffert U., Cohn J.S., Petit-Turcotte C., Tremblay M., Aumont N., Ramassamy C., Davignon J., Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 1999, 843:87-94.
7. Beffert U., Stolt P.C., Herz J. Functions of lipoprotein receptors in neurons. J. Lipid Res 2004, 45:403-409.
8. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab 2007, 27:909-918.
9. Bennett D.A., Schneider J.A., Bienias J.L., Evans D.A., Wilson R.S. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005, 64:834-841.
10. Berg L., McKeel D.W., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., Saunders A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol 1998, 55:326-335.
11. Bertram L. Alzheimer's disease genetics current status and future perspectives. Int. Rev. Neurobiol 2009, 84:167-184.
12. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res 1995, 33:174-178.
13. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
14. Blacker D., Haines J.L., Rodes L., Terwedow H., Go R.C., Harrell L.E., Perry R.T., Bassett S.S., Chase G., Meyers D., Albert M.S., Tanzi R. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997, 148:139-147.
15. Bodzioch M., Orsó E., Klucken J., Langmann T., Böttcher A., Diederich W., Drobnik W., Barlage S., Büchler C., Porsch-Ozcürümez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 1999, 22:347-351.
16. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl) 1991, 82:239-259.
17. Bray N.J., Jehu L., Moskvina V., Buxbaum J.D., Dracheva S., Haroutunian V., Williams J., Buckland P.R., Owen M.J., O'Donovan M.C. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum. Mol. Genet 2004, 13:2885-2892.
18. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet 1999, 22:336-345.
19. Bu G., Maksymovitch E.A., Nerbonne J.M., Schwartz A.L. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J. Biol. Chem 1994, 269:18521-18528.
20. Burke W.J., Miller J.P., Rubin E.H., Morris J.C., Coben L.A., Duchek J., Wittels I.G., Berg L. Reliability of the Washington University Clinical Dementia Rating. Arch. Neurol. 1988, 45:31-32.
21. Byne W., Dracheva S., Chin B., Schmeidler J.M., Davis K.L., Haroutunian V. Schizophrenia and Sex Associated Differences in the Expression of Neuronal and Oligodendrocyte Specific Genes in Individual Thalamic Nuclei. Schizo. Res 2008, 98:118-128.
22. Causevic M., Ramoz N., Haroutunian V., Davis K.L., Buxbaum J.D. Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and cognitive decline or dementia. J. Neuropathol. Exp. Neurol 2003, 62:999-1005.
23. Chételat G., Landeau B., Eustache F., Mézenge F., Viader F., de la Sevette V., Desgranges B., Baron J.C. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 2005, 27:934-946.
24. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem 1987, 162:156-159.
25. Chui D.H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., Suzuki H., Araki W., Inoue H., Shirotani K., Takahashi K., Gallyas F., Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med 1999, 5:560-564.
26. Corder E., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet 1994, 7:180-184.
27. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's Disease in late onset families. Science 1993, 261:921-923.
28. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281:1401-1406.
29. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest 2008, 8:4002-4013.
30. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004, 41:193-202.
31. Desikan R.S., Fischl B., Cabral H.J., Kemper T.L., Guttmann C.R., Blacker D., Hyman B.T., Albert M.S., Killiany R.J. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal. Adv. Neurol 2008, 71:819-825.
32. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V., Stopa E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006, 112:405-415.
33. Dooneief G., Marder K., Tang M.X., Ster Y., Dooneief G. The Clinical Dementia Rating scale: community-based validation of "profound" and "terminal" stages. Neurology 1996, 46:1746-1749.
34. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., Haroutunian V. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 2001, 9:1400-1410.
35. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci 2005, 25:2803-2810.
36. Giannakopoulos P., Hof P.R., Giannakopoulos A.S., Herrmann F.R., Michel J.P., Bouras C. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch. Neurol 1995, 52:1150-1159.
37. Gomez-Isla T., West H.L., Rebeck G.W., Harr S.D., Growdon J.H., Locascio J.J., Perls T.T., Lipsitz L.A., Hyman B.T. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann. Neurol 1996, 39:62-70.
38. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., Relkin N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol 2000, 156:15-20.
39. Grehan S., Tse E., Taylor J.M. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J. Neurosci 2001, 21:812-822.
40. Haroutunian V., Davies P., Vianna C., Buxbaum J.D., Purohit D.P. Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol. Aging 2007, 28:1-7.
41. Haroutunian V., Katsel P., Schmeidler J. Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol. Aging 2009, 30:561-573.
42. Haroutunian V., Perl D.P., Purohit D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol 1998, 55:1185-1191.
43. Haroutunian V., Purohit D.P., Perl D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch. Neurol 1999, 56:713-718.
44. Harr S.D., Uint L., Hollister R., Hyman B.T., Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J. Neurochem 1996, 66:2429-2435.
45. Harrison P.J., Wighton-Benn W.H., Heffernan J.M., Sanders M.W., Pearson R.C. Amyloid precursor protein mRNAs in Alzheimer's disease. Neurodegeneration 1996, 5:409-415.
46. Herz J., Hamann U., Rogne S., Myklebost O., Gausepohl H., Stanley K.K. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988, 7:4119-4127.
47. Herz J., Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest 2001, 108:779-784.
48. Hesse C., Bogdanovic N., Davidsson P., Blennow K. A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease. Dement. Geriatr. Cogn. Disord 1999, 10:452-459.
49. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., Paul S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest 1999, 103:R15-R21.
50. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizarry M.C., Hyman B.T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol 2000, 47:739-747.
51. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
52. Irizarry M.C., Rebeck G.W., Cheung B., Bales K., Paul S.M., Holzman D., Hyman B.T. Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann. N. Y. Acad. Sci 2000, 920:171-178.
53. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St George-Hyslop P.H., Mirra S.S., Mori H. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997, 748:250-252.
54. Johnson S.A., Morgan D.G., Finch C.E. Extensive postmortem stability of RNA from rat and human brain. J. Neurosci. Res 1986, 16:267-280.
55. Jordán J., Galindo M.F., Miller R.J., Reardon C.A., Getz G.S., LaDu M.J. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci 1998, 18:195-204.
56. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., Koo E.H. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest 2000, 106:1159-1166.
57. Kang D.E., Saitoh T., Chen X., Xia Y., Masliah E., Hansen L.A., Thomas R.G., Thal L.J., Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997, 49:56-61.
58. Katsel P., Tan W., Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 2009, 4:e7642.
59. Kinoshita A., Whelan C.M., Smith C.J., Mikhailenko I., Rebeck G.W., Strickland D.K., Hyman B.T. Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J. Neurosci 2001, 21:8354-8361.
60. Knauer M.F., Orlando R.A., Glabe C.G. Cell surface. APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). Brain Res 1996, 740:6-14.
61. Koo E.H., Squazzo S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem 1994, 269:17386-17389.
62. Koo E.H., Squazzo S.L., Selkoe D.J., Koo C.H. Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J. Cell Sci 1996, 109:991-998.
63. Kounnas M.Z., Moir R.D., Rebeck G.W., Bush A.I., Argraves W.S., Tanzi R.E., Hyman B.T., Strickland D.K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995, 82:331-340.
64. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem 1994, 63:601-637.
65. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem 1994, 269:23403-23406.
66. LaDu M.J., Pederson T.M., Frail D.E., Reardon C.A., Getz G.S., Falduto M.T. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem 1995, 270:9039-9042.
67. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci 2007, 8:499-509.
68. Lambert J.C., Pérez-Tur J., Dupire M.J., Galasko D., Mann D., Amouyel P., Hardy J., Delacourte A., Chartier-Harlin M.C. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum. Mol. Genet 1997, 6:2151-2154.
69. Landén M., Hesse C., Fredman P., Regland B., Wallin A., Blennow K. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia 1996, 7:273-278.
70. Lefranc D., Vermersch P., Dallongeville J., Daems-Monpeurt C., Petit H., Delacourte A. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci. Lett 1996, 212:91-94.
71. Lendon C.L., Talbot C.J., Craddock N.J., Han S.W., Wragg M., Morris J.C., Goate A.M. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci. Lett 1997, 222:187-190.
72. Li Y., Cam J., Bu G. Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol. Neurobiol 2001, 23:53-67.
73. Lipska B.K., Deep-Soboslay A., Weickert C.S., Hyde T.M., Martin C.E., Herman M.M., Kleinman J.E. Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol. Psychiatry 2006, 60:650-658.
74. Matsui T., Ingelsson M., Fukumoto H., Ramasamy K., Kowa H., Frosch M.P., Irizarry M.C., Hyman B.T. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res 2007, 1161:116-123.
75. Mauch D.H., Nägler K., Schumacher S., Göritz C., Müller E.C., Otto A., Pfrieger F.W. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294:1354-1357.
76. McDonald C.R., McEvoy L.K., Gharapetian L., Fennema-Notestine C., Hagler D.J., Holland D., Koyama A., Brewer J.B., Dale A.M. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009, 73:457-465. Alzheimer's Disease Neuroimaging Initiative.
77. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
78. Mirra S.S., Vogel F.S., Heyman A. Guide to the CERAD Protocol for the Neuropathological Assessment of Alzheimer's Disease. CERAD. Durham, NC 1987.
79. Mitchell T.W., Mufson E.J., Schneider J.A., Cochran E.J., Nissanov J., Han L.Y., Bienias J.L., Lee V.M., Trojanowski J.Q., Bennett D.A., Arnold S.E. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann. Neurol 2002, 51:182-189.
80. Mochizuki A., Tamaoka A., Shimohata A., Komatsuzaki Y., Shoji S. Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet 2000, 355:42-43.
81. Moestrup S.K., Gliemann J., Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992, 269:375-382.
82. Moir R.D., Lynch T., Bush A.I., Whyte S., Henry A., Portbury S., Multhaup G., Small D.H., Tanzi R.E., Beyreuther K., Masters C.L. Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J. Biol. Chem 1998, 273:5013-5019.
83. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
84. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol 2001, 58:397-405.
85. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994, 264:850-852.
86. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
87. Oleinikov A.V., Zhao J., Makker S.P. Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin. Biochem. J 2000, 347:613-621.
88. Perez R.G., Soriano S., Hayes J.D., Ostaszewski B., Xia W., Selkoe D.J., Chen X., Stokin G.B., Koo E.H. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J. Biol. Chem 1999, 274:18851-18856.
89. Pietrzik C.U., Busse T., Merriam D.E., Weggen S., Koo E.H. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 2002, 21:5691-5700.
90. Pietrzik C.U., Yoon I.S., Jaeger S., Busse T., Weggen S., Koo E.H. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J. Neurosci 2004, 24:4259-4265.
91. Pirttila T., Lehtimaki T., Rinne J., Mattila K., Frey H., Nikkari T. The frequency of apolipoprotein E4 allele is not increased in patients with probable vascular dementia. Acta Neurol. Scand 1996, 93:352-354.
92. Pirttila T., Soininen H., Heinonen O., Lehtimaki T., Bogdanovic N., Paljarvi L., Kosunen O., Winblad B., Riekkinen P., Wisniewski H.M., Mehta P.D. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res 1996, 722:71-77.
93. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 1987, 917:148-161.
94. Preece P., Virley D.J., Costandi M., Coombes R., Moss S.J., Mudge A.W., Jazin E., Cairns N.J. Amyloid precursor protein mRNA levels in Alzheimer's disease brain. Brain Res. Mol. Brain Res 2004, 122:1-9.
95. Purohit D.P., Perl D.P., Haroutunian V., Powchik P., Davidson M., Davis K.L. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch. Gen. Psychiatry 1998, 55:205-211.
96. Qiu Z., Strickland D.K., Hyman B.T., Rebeck G.W. Elevation of LDL receptor-related protein levels via ligand interactions in Alzheimer disease and in vitro. J. Neuropathol. Exp. Neurol 2001, 60:430-440.
97. Rebeck G.W., Harr S.D., Strickland D.K., Hyman B.T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann. Neurol 1995, 37:211-217.
98. Rensen P.C., Jong M.C., van Vark L.C., van der Boom H., Hendriks W.L., van Berkel T.J., Biessen E.A., Havekes L.M. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem 2000, 275:8564-8571.
99. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med 2002, 8:1243-1248.
100. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Review Med 1996, 47:387-400.
101. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest 2000, 12:1489-1499.
102. Shie F.S., LeBoeuf R.C., Jin L.W., LeBoeur R.C. Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport 2003, 14:123-129.
103. Sihlbom C., Davidsson P., Sjögren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem. Res. 2008, 33:1332-1340.
104. Strittmatter J.M., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: High-avidity binding to B-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 1993, 90:1977-1981.
105. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A 1993, 90:8098-8102.
106. Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 5:605-608.
107. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J.D., LaDu M.J., Rostagno A., Frangione B., Ghiso J. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J 2000, 348:359-365.
108. Trommsdorff M., Borg J.P., Margolis B., Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J. Biol. Chem 1998, 273:33556-33560.
109. Ulery P.G., Beers J., Mikhailenko I., Tanzi R.E., Rebeck G.W., Hyman B.T., Strickland D.K. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J. Biol. Chem 2000, 275:7410-7415.
110. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
111. Vassar R., Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron 2000, 27:419-422.
112. Vawter M.P., Tomita H., Meng F., Bolstad B., Li J., Evans S., Choudary P., Atz M., Shao L., Neal C., Walsh D.M., Burmeister M., Speed T., Myers R., Jones E.G., Watson S.J., Akil H., Bunney W.B. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol. Psychiatry 2006, 11:663-679.
113. Winkler K., Scharnagl H., Tisljar U., Hoschützky H., Friedrich I., Hoffmann M.M., Hüttinger M., Wieland H., März W. Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J. Lipid Res 1999, 40:447-455.
114. Wolf H., Grunwald M., Ecke G.M., Zedlick D., Bettin S., Dannenberg C., Dietrich J., Eschrich K., Arendt T., Gertz H.J. The prognosis of mild cognitive impairment in the elderly. J. Neural Transm. Suppl 1998, 54:31-50.
115. Zarow C., Victoroff J. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp. Neurol 1998, 149:79-86.
116. Zerbinatti C.V., Wahrle S.E., Kim H., Cam J.A., Bales K., Paul S.M., Holtzman D.M., Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J. Biol. Chem 2006, 281:36180-36186.
117. Zerbinatti C.V., Wozniak D.F., Cirrito J., Cam J.A., Osaka H., Bales K.R., Zhuo M., Paul S.M., Holtzman D.M., Bu G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. U. S. A 2004, 101:1075-1080.